Sai Parenteral Limited’s Initial Public Offering to Open on Tuesday, March 24, 2026, Price Band Set at Rs 372 – Rs 392 Per Equity Share
Mumbai, March 18, 2026 ( TGN ): Telangana based Sai Parenteral Limited has fixed the price band of Rs 372/- to Rs 392/- per Equity Share of face value Rs 5/- each for its maiden initial public offer.
The Initial Public Offering of the Company will open on Tuesday, March 24, 2026, for subscription and close on Friday, March 27, 2026.
Investors can bid for a minimum of 38 Equity Shares and in multiples of 38 Equity Shares thereafter.
Equity shares outstanding as on date 3,69,08,823 Equity Shares of Rs 5 each.
The IPO is a fresh issue up to Rs 285 crore and an offer-for-sale for up to 3,157, 880 shares by investors – Vikasa India EIF I Fund, Tilokchand Punamchand Ostwal, Devendra Chawla, Bhanwar Lal Chandak, Ashish Maheshwari, Sreelekha Ganta, Padma Guntupalli, Vijay Gondi, Bhautik Mukund Shah and Nilesh Pravinchandra Doshi.
Sai Parenterals is a diversified pharmaceutical formulations company with capabilities in research, development and manufacturing. It is in the business of branded generic formulations and contract development and manufacturing organisation (CDMO) products and services for the domestic and international markets.
Its portfolio includes formulation products across various therapeutic areas like cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology with offerings across dosage forms such as injectables, tablets, capsules, liquid orals and ointments. In the injectables segment, the company has capabilities in sterile manufacturing for critical care and antibiotics, which are delivered through dry powder injections, pre-filled syringes, ampoules, and vials.
The company started its export business in Fiscal 2023 after acquiring two internationally accredited manufacturing units in Hyderabad, Telangana. It owns and operates five manufacturing facilities in India, out of which four facilities are based in Hyderabad, Telangana.
It exports its products to the regulated and semi-regulated markets of Australia, New Zealand, Southeast Asia, Middle East and Africa through its distributors.
The company, through its wholly owned Singapore subsidiary, Sai Parenterals Pte Limited entered into a share purchase agreement dated September 24, 2025, with Noumed Life Sciences Limited (UK), Mark Thulborne, Jo-maree Delac.
Its revenue from operations was Rs 86.9 crore for the six months ended 30 September, 2025 and its net profit was Rs 7.7 crore. Its revenue from operations was Rs 163 crore during FY25 as against Rs 96.7 crore during FY23. Its net profit was Rs 14.4 crore during FY25 as against Rs 4.37 crore during FY23.
Arihant Capital Market is the book-running lead managers, and Bigshare Services Private Limited is the registrar of the offer.
The Offer is being made through the book-building process, wherein not more than 50% of the net offer is allocated to qualified institutional buyers, and not less than 15% and 35% of the net offer is assigned to non-institutional bidders and retail individual bidders respectively.
